Navigation Links
Palatin Technologies Announces Receipt of $4.1 Million from AstraZeneca
Date:2/12/2009

Earns Milestone Payment of Additional $2.5 Million

CRANBURY, N.J., Feb. 12 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Alternext US: PTN) today announced it has received $4.1 million from AstraZeneca relating to an extension of its exclusive research collaboration and license agreement to discover, develop and commercialize compounds that target melanocortin receptors and a clinical trial sponsored research agreement.

Palatin also announced that it has earned a milestone payment of $2.5 million in connection with its collaboration and license agreement with AstraZeneca. Palatin anticipates receiving the $2.5 million in the current calendar quarter.

The $6.6 million received or to be received from AstraZeneca, coupled with $1.7 million that Palatin received from the sale of net operating losses to the State of New Jersey, $700,000 from the sale of non-core fixed assets, and its cash and cash equivalents balance, gives Palatin sufficient cash to fund its projected operations through calendar year 2009.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at www.palatin.com.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008
2. Palatin Technologies to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. Stratus Technologies Partners With Infinity Healthcare Solutions to Resell Availability Products With Its Services
4. Dilon Technologies Leads Molecular Breast Imaging Expansion
5. China Medical Technologies to Announce Financial Results for the Third Fiscal Quarter Ended December 31, 2008 on March 2, 2009
6. VNUS Medical Technologies to Present at the Roth 21st Annual OC Growth Stock Conference
7. Greenway Medical Technologies and Navicure Form Partnership to Streamline Claims Management Process
8. ReBuilder Medical Technologies, Inc. to Change Name to American Med Tech
9. Advanced Wound Technologies Mid-Atlantic, Inc. Announces Name Change and Reverse Stock Split
10. ReBuilder Medical Technologies, Inc. (RBRM) Announces Sales Increase In Jan. 09
11. Scribe Healthcare Technologies, LLC to Integrate BenchMark KB™ in Scribe Complete™ Medical Documentation Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... The report “Poxvirus Infections Pipeline ... therapeutic development for Poxvirus Infections, complete with comparative ... target, mechanism of action (MoA), route of administration ... and featured news and press releases. It also ... for Poxvirus Infections and special features on late-stage ...
(Date:11/28/2014)... November 29, 2014 Recently, PrettyTailor.com has ... dresses for its customers around the world in celebration ... customers, PrettyTailor.com has also launched a special offer on ... more. , As a pioneer in the garment industry, ... products for clients large and small. The business carries ...
(Date:11/28/2014)... The holiday season is fast approaching. As a ... collection of fashionable party dresses. What’s more, the company is ... brand new outfits; the special offer is valid until Dec. ... supplier and it has received a lot of requests for ... designed to flatter various body shapes; they are available in ...
(Date:11/28/2014)... 28, 2014 Now that the holiday ... one of the nation's leading cash-for-junk-cars companies, is improving ... to be more competitive and help bring a little ... festive time of year. , Along with purchasing expensive ... the US also deal with large travel expenses during ...
(Date:11/28/2014)... 2014 Mirena lawsuits ( http://www.mirenalawsuit2014.com/ ... New Jersey’s Bergen County Superior Court, where the ... there is quickly approaching 1,300, Bernstein Liebhard LLP ... shows 1,293 lawsuits now pending in the consolidated ... complications resulting from spontaneous migration of the birth ...
Breaking Medicine News(10 mins):Health News:Poxvirus Infections and Vestibular Diseases Pipeline Market Drugs and Companies Review H2 2014 2Health News:Poxvirus Infections and Vestibular Diseases Pipeline Market Drugs and Companies Review H2 2014 3Health News:Poxvirus Infections and Vestibular Diseases Pipeline Market Drugs and Companies Review H2 2014 4Health News:2015 Wedding Dresses from PrettyTailor.com Available Now 2Health News:Trendy Party Dresses For The Coming Holiday Season From Balfleet.com 2Health News:Rusty's Auto Salvage Increasing Their Cash Offers to Help Drivers Save Throughout the Busy Holiday Season 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 3
... September 11, 2011, one of the most critical challenges that ... victims trapped under debris a painful and tedious race ... been a losing race when relying on drills, saws, and ... and Technology Directorate (S&T) has developed a new tool to ...
... Sept. 21, 2011 Patients at Virginia G. Piper Cancer ... participate in a clinical trial to determine the safety, tolerability ... proteins associated with the most common form of lung cancer, ... and neuroblastoma. The first patient on the study ...
... News) -- Differences in the genetic makeup of prostate cells ... more likely to get prostate cancer and die from it ... a lot of socioeconomic and environmental factors that create differences ... co-author Bi-Dar Wang, assistant research professor of pharmacology and physiology ...
... Administration of the commonly used stimulant drug methylphenidate (Ritalin) was ... study conducted at Massachusetts General Hospital (MGH). The report, ... the first demonstration in mammals of what could be a ... While there are drugs to counteract many of the ...
... NY) Researchers at Albert Einstein College of ... by rheumatologists and the use of immunosuppressant drugs improve the ... could reverse long-standing clinical practice. Their study appeared in the ... At least 1.5 million Americans (more than 90 ...
... Move over, gourmet meal. Apparently cold hard cash and a ... conclusion of new research that examined how people react when ... people salivate when they desire material objects, according to the ... Research . "Merely being exposed to the concept of ...
Cached Medicine News:Health News:Racing against time 2Health News:TGen-Virginia G. Piper Cancer Center launches clinical trial for drug to treat lung cancer 2Health News:Genes May Explain Blacks' Bleaker Prostate Cancer Stats 2Health News:Common stimulant may speed recovery from general anesthesia 2Health News:Common stimulant may speed recovery from general anesthesia 3Health News:Continued treatment for lupus may boost survival of those patients with end-stage kidney disease 2Health News:Cash, Luxury Goods Really Do Get People Salivating: Study 2
(Date:11/26/2014)... , Nov. 26, 2014 Scott Steiger ... most of the world. As an engineer for the past 20 ... member of the military service. He,s been to six of the ... Photo - http://photos.prnewswire.com/prnh/20141126/161076 Photo - http://photos.prnewswire.com/prnh/20141126/161077 ... for travelers, he has a pretty good idea of what,s required. ...
(Date:11/26/2014)... -- Zynerba Pharmaceuticals , Inc., a specialty pharmaceutical ... cannabinoid treatments, today announced that the company will present ... The conference will be held December 2 to 3, ... York . Zynerba,s Chairman and CEO, Armando ... December 2. To listen to a webcast ...
(Date:11/26/2014)... , Nov. 26, 2014 The ... at a rate of 4%, with world market ... Kalorama Information. MRI and other types of medical ... and treatment of numerous medical conditions in children ... and techniques. Kalorama,s report, Medical Imaging Markets ...
Breaking Medicine Technology:Steiger Has Created the First Pill Case Specifically Designed For Travel 2Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3
... Infinity Triglycerides powder reagent once reconstituted ... of single liquid stability to help ... and provide quick result turnaround time. ... Triglycerides powder reagent provides a long ...
... single liquid stable reagent offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The patented ... provides a long shelf life that ...
... Infinity Creatinine single liquid stable reagent ... of single liquid stability to help ... and provide quick result turnaround time. ... Creatinine reagent provides a long shelf ...
... Amylase powder reagent once reconstituted offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... powder reagent provides a long shelf ...
Medicine Products: